ABLYNX ANNOUNCES WARRANT EXERCISE

ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION

GHENT, Belgium, Jan. 20, 2014  (GLOBE NEWSWIRE) --Ablynx [Euronext  Brussels: 
ABLX] today announced, in conformity  with Title II of the  Law of 2 May  2007 
and the Royal  Decree of  14 February 2008,  that an  additional 5,583  common 
shares have  been issued  by the  Company in  exchange for  €27,440.04 as  the 
result of the exercise  of warrants by some  employees and consultants of  the 
Company.

As a result of this transaction, Ablynx now has 48,998,229 shares outstanding.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on  single-domain 
antibody  fragments,  for  a  range  of  serious  human  diseases,   including 
inflammation, haematology, oncology and pulmonary disease. Today, the  Company 
has approximately  30  programmes in  the  pipeline and  seven  Nanobodies  in 
clinical  development.  Ablynx  has   on-going  research  collaborations   and 
significant partnerships with major pharmaceutical companies including AbbVie,
Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis.  The 
Company is headquartered in Ghent, Belgium.

More information can be found on www.ablynx.com.

For more information, please contact Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
 +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx@consilium-comms.com

Pdf version of the press release http://hugin.info/137912/R/1755742/592863.pdf

HUG#1755742
 
Press spacebar to pause and continue. Press esc to stop.